Does Medicare Pay for Ozempic? Coverage Rules, Copays, and Workarounds in 2026

Key Takeaways

• Medicare Part D covers Ozempic for type 2 diabetes when prior authorization criteria are met.
• Medicare does not cover Ozempic when it is prescribed off-label for weight loss alone.
• Typical 2026 Medicare Part D copays for Ozempic range from $50 to $500 per month, depending on plan formulary tier and coverage phase.
• Medicare beneficiaries are excluded from manufacturer copay cards by federal law, including the Novo Nordisk Ozempic savings card.
• The Inflation Reduction Act caps Part D out-of-pocket spending at $2,000 per year starting in 2025, which limits annual Ozempic spending for many enrollees.
• Compounded semaglutide is not covered by Medicare and is paid out of pocket.

Direct answer (40-60 words)

Yes, Medicare Part D covers Ozempic for type 2 diabetes when prior authorization criteria are met, with copays typically ranging from $50 to $500 per month in 2026. Medicare does not cover Ozempic for weight loss alone, since federal law excludes weight-loss drugs from Part D, and Medicare patients are not eligible for the manufacturer savings card.

Table of contents

1. The 30-second answer
2. How Medicare Part D handles Ozempic
3. Why Medicare does not cover Ozempic for weight loss
4. Medicare Part D coverage phases and what you actually pay
5. Prior authorization criteria most plans use
6. The 2025 to 2026 out-of-pocket cap and what it changed
7. Medicare Advantage plan differences
8. Extra Help (Low-Income Subsidy) for qualifying beneficiaries
9. What about Wegovy and Zepbound under Medicare
10. The compounded semaglutide path for Medicare patients
11. FAQ
12. Sources
13. Footer disclaimers

How Medicare Part D handles Ozempic

Medicare Part D is the federal prescription drug benefit. Part D plans are run by private insurers under contract with Medicare, and each plan publishes its own formulary. Almost all Part D plans place Ozempic on a covered tier for type 2 diabetes, typically a non-preferred brand or specialty tier (CMS Part D Formulary Reference 2026).

What that means at the pharmacy counter:

1. Patient hands over the Medicare Part D card.
2. Pharmacy submits the claim.
3. Plan applies its tier rules, prior-authorization requirements, and the patient's current coverage phase.
4. Patient pays the calculated copay or coinsurance.

Most Medicare Part D plans place Ozempic on Tier 3 (non-preferred brand) or Tier 4 (specialty). Tier 3 typically has a flat copay of $40 to $100. Tier 4 typically uses coinsurance of 25 to 33%, which translates to a $250 to $500 patient share on a roughly $1,000 fill.

The prior authorization step matters. Many plans require documentation of:

• Type 2 diabetes diagnosis (ICD-10 code, recent A1C result).
• Prior trial of metformin or contraindication to it.
• BMI documentation if comorbid obesity is present.
• Statement that the prescription is not for weight loss alone.

Without an approved prior authorization, the claim may be rejected and the patient pays cash price (around $940 to $1,150 for a one-month supply).

Why Medicare does not cover Ozempic for weight loss

Federal statute (Social Security Act, Part D coverage rules) explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from required Part D coverage. This rule predates the GLP-1 era and was originally meant to exclude older diet pills.

The current effect:

• Ozempic prescribed for type 2 diabetes is covered.
• Ozempic prescribed off-label for weight loss without diabetes is not covered.
• Wegovy (same active ingredient, branded for weight management) was historically not covered for weight loss alone. In March 2024, CMS clarified that Wegovy could be covered when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and obesity, following the SELECT trial outcomes (Lincoff et al., NEJM 2023). That is a narrow indication, not general weight-loss coverage.
• Zepbound (tirzepatide) for sleep apnea is covered for that specific indication after the FDA's 2024 expansion. For weight loss alone, it is not.

Practical interpretation: if a patient has type 2 diabetes plus obesity, the prescription is written for diabetes management, and the chart documents diabetic control as the goal. Coverage usually goes through. If a patient has obesity only, no diabetes, and no qualifying cardiovascular history, Medicare will not pay for Ozempic.

Medicare Part D coverage phases and what you actually pay

Medicare Part D has historically used a multi-phase structure that changed your share as your annual spending increased. The Inflation Reduction Act simplified the structure starting in 2025.

2026 coverage phases:

Phase	Patient pays	Trigger
Deductible	Up to plan deductible (max $545 in 2026)	First fills of the year
Initial coverage	Tier-based copay or coinsurance	After deductible until $2,000 OOP
Catastrophic	$0	After $2,000 out-of-pocket reached

The $2,000 annual out-of-pocket cap on Part D drug spending is a significant change. For Ozempic patients on coinsurance plans, this often means the highest spending months are January through April, with reduced or zero copays from May through December.

Worked example. A patient on a Part D plan with Ozempic on Tier 4 at 25% coinsurance and a $545 deductible:

• January (first fill): $545 deductible plus 25% of remaining cost. Roughly $700 out of pocket.
• February: 25% of $1,000, or about $250.
• March: 25% of $1,000, or about $250.
• April: 25% of $1,000, or about $250. Cumulative spending hits $2,000 cap mid-fill.
• May through December: $0 copay.

Total annual out-of-pocket: roughly $2,000, regardless of starting price.

Prior authorization criteria most plans use

Prior authorization (PA) is the gatekeeper for Ozempic on Medicare Part D. Plans publish PA criteria in the formulary. Common requirements:

1. Documented type 2 diabetes diagnosis with A1C above a threshold (often 7.0% or higher).
2. Trial of metformin for at least 3 months, or documented intolerance or contraindication.
3. Provider attestation that Ozempic is being prescribed for diabetes, not weight loss.
4. Adequate kidney function (eGFR above plan-specified threshold).
5. Sometimes, a trial of older oral diabetes medications before approving an injectable.

PA approvals last 6 to 12 months and require renewal. A 2024 GoodRx data review found 42% of Medicare Ozempic PAs were approved on first submission, 28% required additional documentation, and 18% were denied without an alternative covered.

If a PA is denied, the prescriber can appeal. The appeal process has multiple levels and can take 30 to 90 days. Medicare beneficiaries denied PA who cannot afford cash price often switch to alternative diabetes medications or to compounded semaglutide.

The 2025 to 2026 out-of-pocket cap and what it changed

The Inflation Reduction Act introduced a $2,000 annual out-of-pocket cap on Part D drug spending starting in 2025 (CMS Inflation Reduction Act Implementation 2025).

What changed:

• The "donut hole" coverage gap was eliminated.
• Once a patient's true out-of-pocket Part D spending hits $2,000 in a calendar year, the plan covers 100% of further covered drugs.
• The cap resets each January 1.
• Beneficiaries can opt into the Medicare Prescription Payment Plan, which spreads the $2,000 over monthly installments rather than concentrating it in early-year fills.

What did not change:

• Coverage rules. If Ozempic is not on the plan's formulary or is denied PA, the cap does not help.
• Off-label exclusions. Ozempic for weight loss alone is still not covered.
• Manufacturer card eligibility. Medicare beneficiaries are still excluded from copay cards.

The cap shifts the math for chronic Ozempic users from "potentially $5,000+ per year" to a hard $2,000 ceiling. For many beneficiaries this is the most significant Medicare drug-pricing change in a decade.

Medicare Advantage plan differences

Medicare Advantage (Part C) plans bundle Part A, Part B, and usually Part D into a single private plan. Drug coverage rules are similar to standalone Part D plans, with some plan-specific differences:

• Some MA plans have lower copays for Tier 3 brands.
• Some MA plans use a closed formulary that excludes Ozempic entirely, requiring a tier exception for coverage.
• MA plans must follow CMS rules for the $2,000 annual cap.
• Some MA plans offer mail-order 90-day fills with reduced copays.

Patients comparing MA plans during open enrollment should check whether Ozempic is on the formulary, what tier, what the prior authorization requirements are, and whether mail-order fills are supported. Medicare's Plan Finder tool at medicare.gov allows direct drug-by-drug comparison.

Extra Help (Low-Income Subsidy) for qualifying beneficiaries

Extra Help, also called the Low-Income Subsidy (LIS), reduces drug costs for Medicare beneficiaries with limited income and resources.

Eligibility (2026):

• Income at or below 150% of the federal poverty level (about $22,590 for an individual or $30,660 for a couple).
• Resources below specified limits (varies year to year).
• Enrolled in Medicare Part A or Part B.

What Extra Help provides:

• Reduced or zero plan premiums.
• Reduced or zero deductible.
• Capped copays on covered drugs (usually $4 to $11 per fill).
• Continued coverage with no donut hole.

For Ozempic, Extra Help can reduce a $250 monthly coinsurance to a fixed $11 copay. Annual spending on Ozempic for an Extra Help beneficiary typically runs under $150 total.

Application is through the Social Security Administration (ssa.gov) or state Medicaid offices. Approval typically takes 30 to 60 days.

What about Wegovy and Zepbound under Medicare

Wegovy. Historically not covered for weight loss alone. Following CMS guidance in March 2024 and the SELECT trial outcomes, Wegovy may be covered for cardiovascular risk reduction in Medicare patients with established cardiovascular disease and obesity (BMI 27+). Plans implement this differently, and prior authorization is uniformly required.

Zepbound. Coverage expanded for obstructive sleep apnea after the FDA's 2024 indication expansion based on the SURMOUNT-OSA trial (Malhotra et al., NEJM 2024). Patients with diagnosed moderate-to-severe OSA and obesity may obtain Zepbound coverage on some plans.

Mounjaro and Rybelsus. Both are diabetes medications and are typically covered on Part D plans for type 2 diabetes with prior authorization, similar to Ozempic.

The pattern across Medicare GLP-1 coverage in 2026: covered for diabetes, sometimes covered for cardiovascular or sleep apnea indications, not covered for general weight loss.

The compounded semaglutide path for Medicare patients

Some Medicare patients who cannot get Ozempic covered (off-label weight loss, denied PA, plan formulary exclusion) turn to compounded semaglutide.

What patients should know:

• Medicare does not cover compounded medications in this category. Patients pay out of pocket.
• Compounded semaglutide is not FDA-approved.
• Pricing through licensed telehealth platforms typically runs $179 to $499 per month.
• Compounded medications are prepared by a state-licensed compounding pharmacy in response to an individual prescription.
• They are drawn from a vial with a U-100 insulin syringe, not delivered in a pre-filled pen.

For a Medicare patient denied Ozempic for weight loss, the cost calculation often comes down to a $940+ cash Ozempic fill versus a $179 to $279 compounded semaglutide fill. The compounded option is usually the lower-cost path when Medicare coverage is not available, but it carries the regulatory differences above.

A licensed clinician should walk through trade-offs, including the differences between FDA-approved and compounded products, before either path begins.

FAQ

Does Medicare cover Ozempic? Yes, Medicare Part D covers Ozempic for type 2 diabetes when prior authorization criteria are met. It does not cover Ozempic for weight loss alone, since federal law excludes weight-loss drugs from Part D.

How much does Ozempic cost on Medicare? Typical 2026 monthly out-of-pocket costs range from $50 to $500 depending on plan formulary tier and coverage phase. The Inflation Reduction Act caps annual Part D spending at $2,000.

Why won't Medicare cover Ozempic for weight loss? Federal statute (Social Security Act Part D rules) excludes "agents when used for weight loss" from required Part D coverage. The exclusion predates GLP-1 medications and applies broadly to any drug prescribed for weight management.

Does Medicare cover Wegovy? Not for weight loss alone. CMS guidance from 2024 allows coverage for cardiovascular risk reduction in patients with established cardiovascular disease and obesity (BMI 27+), following the SELECT trial. Plans require prior authorization.

Does Medicare cover Zepbound? Coverage expanded for obstructive sleep apnea following the SURMOUNT-OSA trial. Patients with diagnosed moderate-to-severe OSA and obesity may qualify on some plans. Coverage for weight loss alone remains excluded.

Can I use the Novo Nordisk savings card with Medicare? No. Medicare beneficiaries are excluded from manufacturer copay cards by federal law (the anti-kickback statute). The savings card applies only to commercially insured patients.

What is the Medicare Part D out-of-pocket cap for 2026? $2,000. Once a patient's true out-of-pocket Part D drug spending in a calendar year reaches $2,000, the plan covers 100% of further covered drugs. The cap resets each January 1.

How do I get prior authorization for Ozempic on Medicare? Your prescribing provider submits a PA form to your Part D plan. Required documentation typically includes type 2 diabetes diagnosis, A1C results, prior metformin trial or contraindication, and confirmation that the prescription is for diabetes, not weight loss.

Does Medicare Advantage cover Ozempic? Most Medicare Advantage plans cover Ozempic for type 2 diabetes with prior authorization. Coverage rules and tier placement vary by plan. The $2,000 annual cap applies to MA plans with prescription drug coverage.

Can Extra Help reduce my Ozempic cost? Yes. Extra Help (Low-Income Subsidy) caps Ozempic copays at roughly $4 to $11 per fill for qualifying beneficiaries. Eligibility requires income at or below 150% of the federal poverty level.

What if my Part D plan denies Ozempic? Your provider can appeal the denial through the plan's grievance process. If the appeal fails, options include trying an alternative diabetes medication, switching to a different Part D plan during open enrollment, or pursuing compounded semaglutide as an out-of-pocket alternative.

Is compounded semaglutide covered by Medicare? No. Medicare does not cover compounded medications in this category. Patients pay out of pocket through licensed telehealth platforms or local compounding pharmacies.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Part D Drug Coverage Guidelines 2026.
2. Centers for Medicare & Medicaid Services. Inflation Reduction Act Part D Implementation 2025.
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
4. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA). N Engl J Med. 2024.
5. Social Security Act. Section 1860D-2(e)(2)(A) Part D Excluded Drugs.
6. CMS Memorandum on Anti-Obesity Medication Coverage Under Part D. March 2024.
7. Novo Nordisk. Ozempic Prescribing Information. Revised 2024.
8. Medicare.gov. Plan Finder Tool. Accessed Q1 2026.
9. Social Security Administration. Extra Help With Medicare Prescription Drug Plan Costs 2026.
10. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024.
11. Federal Anti-Kickback Statute. 42 U.S.C. § 1320a-7b. Restrictions on manufacturer copay assistance for federal beneficiaries.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicare is a federal program of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these organizations.